Need professional-grade analysis? Visit stockanalysis.com
$5.73M
N/A
N/A
N/A
Psyence Biomedical Ltd. Common Shares (PBM) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $9.03, up 0.67% from the previous close.
Over the past year, PBM has traded between a low of $0.64 and a high of $449.22. The stock has lost 94.6% over this period. It is currently 98.0% below its 52-week high.
Psyence Biomedical Ltd. Common Shares has a market capitalization of $5.73M.
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company has a strategic collaboration with PsyLabs to produce Ibogaine. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
Side-by-side comparison against top Healthcare peers.